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Abstract 32 
Objectives: Platelets rich plasma (PRP) therapy is widely used in enhancing the recovery of skeletal 33 
muscle from injury. However, the impact of intramuscular delivery of PRP on hematologic and 34 
biochemical responses has not been fully elucidated in exercise-induced muscle damage (EIMD). 35 
 Design: Moderately active male volunteers participated in this study and were assigned to a  36 
control group (CONTROL, n=6) and platelet rich plasma administration group (PRP, n=6).The 37 
subjects  performed exercise with a load of 80 % one repetition maximum (1RM) maximal 38 
voluntary contraction of the elbow flexors until point of exhaustion of the non-dominant arm was 39 
reached. The arms were treated with saline or autologous PRP post-24h EIMD. Venous blood 40 
samples were obtained in the morning to establish a base-line value and 1-4 days post-exercise and 41 
were analyzed for serum ferritin, iron, iron binding capacity (IBC), creatinine kinase (CK), lactate 42 
dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT). 43 
 Results: The baseline levels of plasma iron, ferritin, IBC, CK, LDH, AST and ALT were similar in 44 
both the control and PRP groups. However, 24 h following exercise a significant increase in these 45 
parameters was observed in both groups between 1-4 days during the recovery period. Interestingly, 46 
PRP administration decreased plasma iron levels compared to the control on the second day post-47 
exercise. Plasma IBC increased in PRP group from day 2 to 4 post exercise compared to the control 48 
group whilst PRP administration had no effect on plasma ferritin, CK, AST, ALT and LDH.  49 
Conclusions: Acute exhaustive exercise increased muscle damage markers, including plasma iron, 50 
IBC and ferritin levels, indicating muscle damage induced by exercise.  PRP administration 51 
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improves inflammation by reversing the increase in the iron levels post-exercise without displaying 52 
any myotoxicity and may have a role to play in the recovery of exercise-induced muscle damage.              53 
Key Words: platelet-rich plasma, plasma iron, ferritin, exercise-induced muscle damage  54 
1. Introduction 55 
Recently platelet-rich plasma (PRP), an autologous derivative of whole blood containing a 56 
supraphysiological concentration of platelets has gained increasing popularity in both the scientific 57 
literature and the wider media for its potential application in the treatment of traumatic 58 
musculoskeletal and sports-related injuries, cancer biology, and dermatology. In addition, it has 59 
been reported that PRP administration may improve recovery from tendon and muscle injuries1,2. 60 
Biologic healing utilizes the normal mechanisms for tissue repair and incorporates these at the site 61 
of injury. Blood components such as platelets migrate to the injury site and play an important role in 62 
tissue repair. Platelets contain various growth factors and cytokines that initiate and promote 63 
healing by stimulating cell migration, cell proliferation, angiogenesis, and matrix. Other important 64 
bioactive factors released from platelets include histamine and serotonin and these platelet growth 65 
factors enhance DNA synthesis, chemotaxis, angiogenesis, increase collagen deposition, and 66 
stimulate synthesis of extracellular matrix3. 67 
It is well established that an unaccustomed and strenuous exercise in the trained and 68 
untrained individual can induce skeletal muscle damage4; this phenomenon is commonly known as 69 
“exercise-induced muscle damage” (EIMD) and is determined by the type, intensity and duration of 70 
exercise5. Moreover, in sports, the eccentric/concentric type of exercise has been used as a specific 71 
training model for muscle strength improvement during training sessions. However, symptoms of 72 
EIMD include reduced muscular force, increased stiffness, swelling delayed onset muscle soreness 73 
(DOMS), and an increased blood activity of muscle proteins such as creatine kinase (CK˃ 10.000 74 
IU/L)4, alanine transaminase (ALT)6, aspartate transaminase (AST)6, lactate dehydrogenase 75 
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activity7 and this may have a negative impact on performance4.  Moreover, EIMD initiates an 76 
inﬂammatory response associated with secondary muscle damage and remodeling8 since during the 77 
acute phase, both neutrophils and phagocytic macrophages can release reactive oxygen and nitrogen 78 
species and remove debris by phagocytosis9. Moreover, recent studies have reported the levels of 79 
the iron-regulatory hormone hepcidin are also increased after exercise10-12. Hepcidin is a liver-80 
produced peptide hormone, up-regulated in response to elevated iron levels and the inflammatory 81 
cytokine interleukin-6 (IL-6)13,14 and an increase in hepcidin levels usually occurs as a homeostatic 82 
response to inflammatory stimuli namely the IL-6 or elevated iron levels13. Peeling et al. reported 83 
that  inflammation, hemolysis, serum iron, ferritin, and urinary hepcidin were elevated in the high 84 
intensity interval post- running session11. As such, the post-exercise hepcidin response is likely to 85 
be homeostatic in nature, to help control and reduce the elevated levels of serum iron resulting from 86 
the exercise-induced hemolysis15. 87 
Many studies have been published proposing various methods for treating DOMS, including 88 
cryotherapy, anti-inﬂammatory medication, stretching, hyperbaric oxygen, homeopathy, ultrasound, 89 
L-carnitine, rest, light exercise and electromagnetic shields16-21. For example, non-steroidal anti-90 
inflammatory drugs (NSAIDs) are routinely prescribed to alleviate EIMD-related symptoms and 91 
restore normal physical function of the muscle22. However, it has been reported that NSAIDs act by 92 
blocking COX and thus they may have a detrimental effect on muscle regeneration and super-93 
compensation20. Moreover, there is strong to moderate evidence that intramuscularly injected local 94 
anaesthetics and NSAIDs are myotoxic. The administration of PRP has also been reported to induce 95 
myotoxicity, however the evidence is conflicting and further studies are required to confirm this as 96 
well as the possible myotoxic effects of corticosteroids23. Furthermore, clinical and 97 
histopathological studies have shown the potential myotoxicity of intramuscular injections in both 98 
animals and humans24,25, resulting in pain at the injection site and histopathological changes of 99 
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inﬂammation, necrosis and ﬁbrosis24,25. Besides histological changes, the local plasma creatine 100 
kinase (CK) concentration is the most commonly used valid marker for skeletal muscle 101 
myotoxicity26-28. There is conﬂicting evidence regarding the myotoxicity of intramuscular PRP 102 
injections. Two studies used an animal muscle injury model and reported increased signs of 103 
regeneration, less necrosis and less granulomatous tissue in the muscles injected with, PRP29,30 and 104 
autologous conditioned serum (ACS)31than in control muscles on histological evaluation for up to 2 105 
weeks. However, information regarding the myotoxicity of intramuscular PRP injection or the 106 
cross-talk between hematologic and biochemical response has not been reported in exercise-induced 107 
muscle damage. Therefore, we hypothesized that intramuscular PRP injection might improve 108 
inflammation and beneficial effect on DOMS and muscle damage induced by exercise without 109 
mytoxicity effects. The objective of the present study was to investigate whether the myotoxicity 110 
effects of the intramuscular PRP injection can provide an effective recovery strategy for attenuating 111 
DOMS and muscle damage induced by high-intensity muscle exercise in humans.    112 
 113 
2. Methods 114 
2.1. Study Design 115 
Twelve moderately active male volunteers participated in this randomized double-blind 116 
placebo-controlled trial to verify the effects of the intramuscular PRP injection on hematologic, 117 
biochemical response and mytoxicity on muscle recovery after an eccentric/concentric exercise. 118 
Subjects were randomly placed into two groups: PRP (n=6) and CONTROL (n=6) and they had not 119 
been involved in any regular weight-training program and had no history of injury to the arm, 120 
shoulder and elbow region. The nature and the risks of the experimental procedures were explained 121 
to the subjects, and signed informed consent to participate in the study was obtained.  Before the 122 
test session, participants were examined and checked by the use of routine blood analysis by a 123 
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medically qualified practioner. Ethical approval was obtained from The Balikesir University 124 
Medical Faculty Ethics Committee (2013/14) and each participant gave written informed consent 125 
prior to the study. 126 
2.2. Muscle Damage Exercise Protocol 127 
For the exercise-induced muscle damage test, subjects were seated on a bench with their arm 128 
positioned in front of their body and resting on a padded support, such that their shoulder was 129 
secured at a flexion angle of 0.79 rad (45°) and their forearm was maintained in the supinated 130 
position throughout the exercise. Subjects were repeatedly weight-loaded upon dumbbell lowering 131 
to achieve a 80% of maximum voluntary contraction (MVC), 2-min rest between the sets of elbow 132 
extension from the flexed position at 900 to fully extended position slowly over 5 s, until exhaustion 133 
was experienced. The subjects were also given verbal encouragement by the investigator to 134 
maintain constant speed throughout the procedure. They were instructed to continue their normal 135 
activities and to abstain from any strenuous exercise at least two weeks before the experiment. 136 
Moreover, they were asked to continue their usual food intake, not to change the amount or 137 
frequency of dietary meat and not to use any dietary supplements, anti-inflammatory drugs, or 138 
anything else that could affect muscle soreness and damage until the end of the study.  139 
2.3. Platelet-rich plasma and placebo 140 
Each participant based on computerized randomization lists to either receive placebo 141 
(saline) injection or PRP injection in non-dominant arms with post-24h DOMS exercise. PRP 142 
preparation was obtained from eight millilitres of peripheral blood which was drawn from the 143 
dominant arm and the samples were centrifuged for 9 minutes at 3500 revolutions per minute (H-144 
19F, RegenCentrigel) according to manufacturers recommendation (Regen ACR-C, Regen Lab, 145 
Switzerland). Subsequently, 4 ml of PRP was injected using a 20-gauge needle into the pain full 146 
region of the non-dominant arm under sterile aseptic conditions. This kit produces 4 mL of PRP 147 
 7 
 
7 
from 8 mL citrated blood. Therefore final platelet concentration is approximately ≤2 fold over 148 
whole blood platelet concentration. Platelet recovery is reported to be > 95% and a leukocyte 149 
recovery of 58% .  150 
Venous blood samples were collected pre-, and 4 days post-exercise, and analyzed for complete 151 
blood counts (WBC, RBC, Hb) , serum ferritin, iron (Fe), iron binding capacity (IBC), creatinine 152 
kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine 153 
aminotransferase (ALT) as markers of muscle damage and inflammation. 154 
2.4. Hematological analysis 155 
For analyses of serum iron (Fe),  iron binding capacity (IBC),and ferritin blood samples 156 
were collected without any additive and after centrifugation sera were stored at-20°C until analyzed.  157 
Iron and IBC were measured spectrophotometrically in an Advia 1800 analyzer (Siemens 158 
Healthcare, Erlangen, Germany) and ferritin was measured by immunoturbidimetric assay in an 159 
Olympus AU400 analyzer (Beckman Coulter, CA, USA).  160 
2.5. Biochemical analysis 161 
Following centrifugation at 825 xg for 10 min, serum was analyzed for ALT, AST, CK and 162 
LDH activities using commercially available kits in a chemistry autoanalyser (Cobas Integra 800; 163 
Roche Diagnostic GmbH; Mannheim, Germany). 164 
2.6. Statistical Analysis 165 
All calculations were performed using SPSS software (SPSSInc, Chicago, Illinois, USA). 166 
The values of serum Fe, IBC, ferritin, ALT, AST, LDH, and CK are presented as raw values as the 167 
area under the curve (AUC) during the experimental period. The AUC was calculated as the sum of 168 
four or five trapezoid areas separated by each supplement time point. Two-way mixed model 169 
analyses of variance (2 group X 5 times) with repeated measures were used. Diﬀerences in 170 
continuous variables between groups were assessed using Independent t-test and between multiple 171 
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points within the same group were analyzed using student’s paired t-test.   Data are expressed as 172 
means ± SE and the level of significance was set at p˂0.05. 173 
 174 
3. Results 175 
There was no difference in body weight, height, age and exercise performance had no 176 
significant differences between PRP and CONTROL (Table 1, p ˃0.05). The baseline values for 177 
plasma Fe, IBC, ferritin, AST, ALT, LDH and CK values were similar between the CONTROL and 178 
the PRP administered group (p ˃0.05). However, 24 h following exercise, the plasma Fe, IBC, 179 
AST, ALT, LDH and CK values significantly increased in the CONTROL and the PRP 180 
administered group on day 1 to 4 post exercise muscle damage (P˂ 0.01, Fig. 1-5). Acute 181 
exhaustive muscle exercise also increased the plasma ferritin levels in control and PRP group (P˂ 182 
0.001 and P˂ 0.05) respectively, Fig.3. Interestingly, PRP administration decreased plasma iron 183 
levels (P= 0.002) compared to the control group but this was only observed on the day 2-3 post-184 
exercise-induced muscle damage (Fig. 1). Moreover, plasma IBC levels were increased in PRP 185 
group from day 1 to 4 post exercise compared to control group (P ˂ 0.05, Fig. 2). In contrast, PRP 186 
administration had no effect on plasma ferritin (Fig. 3), AST, ALT (Fig. 4), LDH and CK levels 187 
(Fig. 5). 188 
Insert Table 1 here 189 
Insert Figure 1 here 190 
Insert Figure 2 here 191 
Insert Figure 3 here 192 
Insert Figure 4 here 193 
Insert Figure 5 here 194 
 195 
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4. Discussion 196 
In this paper we report the effect of single dose of intra-muscular platelet rich plasma on 197 
iron levels in in exercise-induced muscle damage. This was a pilot study in which 6 subjects 198 
participated in the control group and test group. Acute exhaustive exercise increased muscle 199 
damage markers, including plasma iron, IBC and ferritin levels were increased confirming exercise-200 
induced muscle damage. PRP administration resulted in improved muscle recovery from injury 201 
without displaying any myotoxicity.  Many methods have been utilised for the treatment of DOMS, 202 
including cryotherapy, anti-inﬂammatory medication, stretching, hyperbaric oxygen, homeopathy, 203 
ultrasound, L-carnitine, rest, light exercise and electromagnetic shields16-19. Inflammatory 204 
conditions have been essentially treated by the use of non-steroidal anti-inflammatory drugs 205 
(NSAIDs) although they are ineffective in reducing muscle pain and do not increase muscle 206 
performance during DOMS20-22,32-34. As an alternative to conventional treatments, platelet-rich 207 
therapy has been applied due to its potential in accelerating muscle healing and reducing a player’s 208 
injury time. As far as we are aware, this study is the first to examine the effect of intramuscular PRP 209 
administration on DOMS and muscle damage markers also post exercise-induced muscle damage 210 
during the recovery period in healthy human volunteers. Importantly, our results show that the acute 211 
exhaustive muscle exercise increased the plasma iron, IBC and ferritin level in both groups. Our 212 
findings on plasma iron, IBC and ferritin response to acute exhaustive exercise are in agreement 213 
with previous reports10-13. which also reported an increase in serum iron, IBC and ferritin levels 214 
which was linked to the intensity of the exercise. It seems the increase in serum ferritin levels also 215 
led to an increase in plasma iron and hepcidin levels. A majority of publications have reported an 216 
elevated hepcidin levels 24 h post exercise, preceded by acute increase in serum iron and 217 
inflammation parameters10-13, 35. However, we did not measure the post- exercise hepcidin levels in 218 
this study.  The present study indicates that post-exercise serum iron, IBC and ferritin levels are 219 
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induced as a result of inflammatory response due to exhaustive muscle exercise. Speculatively, 220 
acute exhaustive exercise increased the free iron that enters the plasma and has a reduction-221 
oxidation (redox) potential, which may promote free radical formation as a result of Fenton and 222 
Harber–Weiss reactions and can result in oxidative damage to tissues36. Interestingly, in this study it 223 
was observed that PRP administration reversed the observed increase in plasma iron level due to 224 
muscle damage 2-3 days post-exercise. Furthermore, plasma IBC levels were up-regulated in PRP 225 
group from day 1 to 4 post-exercise.  On the other hand PRP administration depressed the plasma 226 
ferritin levels during the recovery phase compared to control values, but did not reach statistical 227 
significance. These results are novel and to the best of our knowledge, no data exists concerning the 228 
acute effect of intramuscular PRP administration on plasma iron, IBC and ferritin levels parameters 229 
during recovery period in an acute exercise-induced muscle damage model.  In general, related 230 
studies have reported that PRP treatment has anti-inflammatory properties through its effects on the 231 
canonical nuclear factor κB signalling pathway in multiple cell types including synoviocytes, 232 
macrophages and chondrocytes37. In addition, PRP treatment has suppressed tendon cell 233 
inflammation in vitro and in vivo, marked by the upregulation of COX-1, COX-2 and mPGES-1 234 
expression with highly PGE2 production38. Additionally, the present study demonstrated that 235 
intramuscular PRP injection plays a key role as an anti-inflammatory by suppressing effect of 236 
increased free iron in plasma during the muscle damage recovery. Evidently, we have previously 237 
shown that elbow flexors muscle strength peak torque values were improved after PRP 238 
administration when compared to the control arm, this  occurred on the same day (second day) 239 
when the serum iron level declined post exercise-induced muscle damage (Unpublished data).    240 
Serum CK concentration is the most sensitive indicator of muscle damage and it begins to 241 
rise approximately 2-12 h after the exhaustive exercise. Exhaustive physical exercise increases 242 
serum enzyme activities such as CK, AST, LDH and ALT hence these are considered as markers 243 
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for the muscular damage derived from intense exercise39. The increased activities of CK and LDH 244 
in serum after exhausted exercise could act as signals, attracting neutrophils to the damaged muscle 245 
and initiating the inflammatory response. The maintenance of high CK activities after recovery 246 
could be and indicator of muscle repair40-42. Our result demonstrate that CK, AST, ALT and LDH 247 
levels increased post-exercise during the DOMS period in both groups, indicating muscle damage. 248 
On the other hand, CK concentration is the most commonly used valid marker for skeletal muscle 249 
myotoxicity in the intramuscular injections26-28. Although intramuscular PRP injections are 250 
commonly used, there is only limited evidence base for myotoxicity in animals models29-31 and 251 
these studies reported increased signs of regeneration of the muscle whilst necrosis and 252 
granulomatous tissue was decreased in the muscle injected with PRP  when compared to the 253 
control, however, no response to CK levels was reported  in these studies29-31. Limited human 254 
studies have been shown that intramuscular injection of lidocaine43 and bupivacaine (20 ml)44 lead 255 
to an increase in CK levels. Our findings showed that the plasma level of CK was increased in 256 
response to exhaustive exercise, however, PRP administration did not alter CK levels in the PRP 257 
group compared to control. Hence, intramuscular PRP injection did not show mytoxicity in 258 
exercise- induced model.   259 
5. Conclusion 260 
Our study results indicate that an acute exhaustive exercise increased muscle damage 261 
markers, including plasma iron, IBC and ferritin levels, indicate muscle damage due to exercise- 262 
induced. PRP administration improved the inflammatory resoponse by reversing the observed 263 
increase in iron levels and may have a role to play in the recovery of exercise-induced muscle 264 
damage. Evidently, intramuscular PRP injection had no effect on CK levels, indicating that it is not 265 
myotoxic.   266 
 267 
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